There is limited evidence from previous studies that sitagliptin can reduce the levels of parameters of liver tests (including SGPT, SGOT, Gamma-glutamyl Transferase (gammaGT)) in patients with NAFLD and even improve histologic features of NAFLD/NASH),16,17,39 but further research is needed in the field. This evidence concerns the gene GOT1 and metabolic dysfunction-associated steatotic liver disease.